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Abstract
Background Recent studies have suggested that various
cytokines may be important players in the development and
progression of chronic pancreatitis (CP) and pancreatic
adenocarcinoma (PC).
Aims We studied endothelial dysfunction and subclinical
inflammation in patients with newly diagnosed pancreatic
adenocarcinoma and CP.
Methods A total of 45 patients were included in the
present investigation, 27 with CP and 18 with PC. In
addition, the study included 13 age- and body weight-
matched healthy subjects served as controls. In all subjects,
plasma adiponectin, TNF-alfa, interleukin 6 (IL-6), inter-
leukin 1beta (IL-1b), E-selectin, thrombomodulin, adhe-
sion molecules ICAM and VCAM, and endothelin-1 were
assessed.
Results PC and CP patients as compared with controls
had significantly greater plasma adiponectin (13,292 and
12,227 vs 5408 ng/ml; p\ 0.0003), TNF-alfa (22.1 and
23.1 vs 13 pg/ml; p\ 0.0002), and IL-6 (6.6 and 7.3 vs
3.3 pg/ml; p\ 0.0001). Moreover, there was significantly
higher concentration of ICAM (931 and 492 vs 290 ng/ml;
p\ 0.005) and VCAM (1511 and 1080 vs 840 ng/ml;
p\ 0.01) in PC and CP patients. When PC and CP patients
with and without diabetes were considered separately, there
was no difference in adiponectin, cytokines, and parame-
ters of endothelial dysfunction.
Conclusion In summary, our data indicate that patients
with CP and PC express high levels of several cytokines
compared with healthy individuals, especially adiponectin,
TNF-a and IL-6. Serum TNF-a and ICAM concentrations
coordinately increase in advanced CP. Furthermore, espe-
cially in PC subjects, elevated markers of endothelial
dysfunction are present. This study provides additional
evidence that changes in inflammatory cytokine and
adhesion molecules in PC and CP are not likely related to
endocrine disorders.
Keywords Pancreatic adenocarcinoma  Chronic
pancreatitis  Inflammation  Cytokines
Introduction
Chronic inflammation is typically associated with many
types of human malignancies [1]. Inflammatory bowel
diseases provide convincing evidence for the association
between chronic inflammation and malignant diseases in
colon. Kate et al. [2] showed that proinflammatory
cytokines are capable of enhancing the adhesion of human
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most likely by the up-regulation of adhesion molecules to
the endothelium. In general, the inflammatory reaction
leads to the activation of leukocytes and monocytes with
the release of proinflammatory cytokines and reactive
oxygen species. Sustained cell proliferation in the milieu of
inflammatory cells, elevated levels of growth factors,
activated stroma, and DNA-damaging agents promote
neoplastic transformations [1]. Chronic pancreatic inflam-
mation is mediated by cytokines, reactive oxygen species,
up-regulated proinflammatory pathways, and immune cell
infiltrates [3, 4]. Moreover, cytokine levels correlate with
phenotypic manifestations of carcinoma and with prognosis
both in patients with hematologic malignancies and in
patients with solid tumors [5]. Cytokines have been also
shown to play a role in different processes in the course of
pancreatic carcinoma and chronic pancreatitis (CP), such as
cachexia, asthenia, and impaired glucose metabolism.
Understanding the biology and pathogenesis of CP and
pancreatic carcinoma may help to improve current—lar-
gely ineffective—treatment.
Pancreatic adenocarcinoma (PC) is one of the five
leading causes of cancer-related deaths. Patients with PC
have very poor prognosis—in the first year, more than 90 %
patients die, and the 5-year survival is\5 % [6]. At the time
of diagnosis, only up to 20 % of patients suffering from PC
are eligible for surgical resection. This is largely due to the
fact that this type of cancer has rapidly progressive course,
gives few symptoms, and has high metastatic potential and
low responsiveness to chemotherapy, radiotherapy, and
immunotherapy. Histologically, an important element of PC
is the intensely desmoplastic stroma, which may be related
to the inflammatory response in PC [7]. The inflammatory
cell clusters are mainly found in areas of fibrosis. The major
determinants of pancreatic fibrosis are the pancreatic stel-
late cells that function as activated myofibroblasts in PC.
These cells have been identified as major source of extra-
cellular matrix proteins but have also been involved in the
modulation of local immune reaction by production and
secretion of cytokines and chemokines [8]. As mentioned
above, cytokines have potent immune regulatory and
growth regulatory effects that may be involved in the
pathogenesis of pancreatic carcinoma. That is why, modu-
lating inflammatory factors may offer attractive pathway for
novel, non-surgical approach in PC treatment.
Aims
We studied endothelial dysfunction and subclinical
inflammation in patients with newly diagnosed pancreatic
adenocarcinoma (PC) and CP compared to healthy volun-
teers. Cytokines and adhesion molecules levels were ana-




Patients were enrolled from the Department of Digestive
Tract Diseases, Medical University of Lodz and Outpa-
tients Gastroenterology Unit. A total of 45 Caucasian
patients were included in the present investigation, 27 with
CP (17 men and 10 women, aged 20–68 years) and 18 with
newly diagnosed pancreatic cancer (4 men and 14 women,
aged 49–81 years). Thirteen healthy, age-, gender-, and
BMI-matched subjects were included into the control
group.
Only patients with confirmed (through aspiration biopsy
or surgical resection sample) diagnosis of ductal pancreatic
adenocarcinoma were included into the study. Among PC
patients, six (33 %) underwent surgical tumor resection,
whereas 12 (67 %) have unresectable tumors. Among the
patients with pancreatic adenocarcinoma, 12 (67 %) had
lymph node metastases at the time of the study, eight
(44 %) had distant metastases, and five (28 %) had dia-
betes at the time of the cancer diagnosis for less than
3 years. Diabetes diagnosis was based according to WHO/
ADA criteria [9]. Moreover, in eight (44 %) PC patients
mean BMI levels was within normal range. Five patients
(28 %) had BMI lower than 20 kg/m2, and five had above
25 kg/m2. Clinicopathologic data were gathered retro-
spectively for each case from the patient’s medical records.
Detailed subjects’ characteristics are presented in Table 1.
The diagnosis of CP was based on the following criteria:
presence of a typical history of recurrent attacks of pan-
creatitis and anatomical abnormalities such as calcifica-
tions and/or pancreatic ductal irregularities present in
pancreatic imaging [10]. In the CP group, 23 with alcohol-
related disease and four with idiopathic disease were
included. ACP (alcoholic CP) was diagnosed in patients
who consumed more than 80 g/day (males) and 40 g/day of
Table 1 Baseline characteristics of pancreatic cancer patients
Pancreatic cancer
(n = 18)
Mean age (years ± SD) 69.61 ± 8.93
Gender (M/F) 4/14
Primary tumor localization:
Head 16 (89 %)
Body/tail 2 (11 %)
Lymph node metastases 12 (67 %)
Distant metastases 8 (44 %)
Jaundice 12 (67 %)
Diabetes 5 (28 %)
BMI (kg/m2) 22.18 ± 4.06
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alcohol (females) for[5 years before the first symptoms of
the disease. ICP (idiopathic CP) was diagnosed when
possible etiological factors such as alcohol abuse, meta-
bolic disorders, anatomic, traumatic causes, and positive
family history were absent. The mean duration of CP was
6.3 ± 4.51 years. The onset of CP was defined as the ini-
tial manifestation—first episode of acute pancreatitis. The
Cambridge classification was used to grade severity of CP
[10]. In CP group, six patients had indications for surgical
intervention and 14 for endoscopic treatment due to
intractable pain, pancreatic stones, pseudocysts, common
bile stenosis, or suspicion of pancreatic cancer. Charac-
teristics of CP patients are presented in Table 2.
Smoking was defined as having smoked C10 cigarettes
per day for C2 years. According to this definition, 13
(72 %) of patients with pancreatic adenocarcinoma and 22
(81 %) of CP patients were smokers.
In the controls, blood samples were collected when they
had no infection, were not receiving any medications, and
did not have any recent (\3 months) history of any acute
illnesses. All patients with PC and CP as well as healthy
controls provided informed, written consent for the use of
their samples, and the study was approved by the Ethics
Committee of Medical University of Lodz.
Blood Analysis
At 8 am, fasting blood samples were collected from
patients and healthy controls. All blood samples were
stored at -20 C until laboratory workup. None of the
samples were previously thawed. The plasma concentra-
tions of adiponectin, TNF-a, interleukin 6 (IL-6), inter-
leukin 1beta (IL-1b), E-selectin, adhesion molecules
sICAM-1, and sVCAM-1 have been measured with an
enzyme-linked immunoassay (ELISA, R&D Systems,
USA). The limit of detection of TNF-a was determined to
be 1.6 pg/ml and adiponectin 0.246 ng/ml. The minimum
detectable of IL-6 and IL-1b was determined to be,
respectively, 0.7 and 1 pg/ml. Endothelin-1 was measured
with a sensitivity of 1.0 pg/ml with the intra-assay coeffi-
cients of variation 4.6 % and the inter-assay CVs 6.5 %.
E-selectin was measured with a sensitivity of 0.009 ng/ml
with the intra-assay coefficients of variation 6.6 % and the
inter-assay CVs 7.3 %. The minimum detectable of ICAM-
1 was 0.096 ng/ml and VCAM-1 was 0.6 ng/ml. The
plasma thrombomodulin has been analyzed with ELISA
(American Diagnostica Inc.) with the intra-assay coeffi-
cients of variation 4.0 % and the inter-assay CVs 5.2 %.
Statistical Analysis
The distribution of categorical variables was assessed with
the use of Chi-squared test or—if subgroup numbers were
lower than 5—with the exact Fisher test. The differences
between the means of continuous variables were assessed
with the Student’s t test. Conditional logistic regression
models were used for estimating odds ratio and 95 %
confidence interval (95 % CI) to evaluate the association of
each variable with pancreatic cancer. Linear regression
analysis was used to determine correlation coefficients
between various parameters. The statistical calculations
were carried out using StatView-J 5.0 statistical software
(SAS Institute, Cary, NC). Differences with a p value of
less than 0.05 were considered to be statistically
significant.
Results
Circulating Concentrations of Adiponectin
Plasma levels of adiponectin were significantly higher in
PC patients (mean cytokine level: 13,292 ng/ml; range:
9542–22,446 ng/ml) and CP patients (12,227 ng/ml; range:
8674–16,751 ng/ml) as compared with the controls
(5408 ng/ml; range: 3933–7799 ng/ml) (p\ 0.0003), but
there was no difference in adiponectin levels between CP
and PC patients (Fig. 1). There was also no relationship
between adiponectin plasma level and clinical data,
including alcohol and smoking of analyzed PC and CP
patients.
Table 2 Baseline characteristics of chronic pancreatitis patients
Chronic pancreatitis (n = 27)
Mean age (years ± SD) 46.82 ± 10.85
Gender (M/F) 17/10
Etiology
Alcoholic 23 (85 %)
Idiopathic 4 (15 %)
Duration of CP
\5 years 18 (67 %)
[5 years 9 (33 %)
Smoking 22 (81 %)
Calcifications 21 (78 %)
Diabetes 12 (44 %)
Cambridge classification:
II 12 (44 %)
III 15 (56 %)
Endoscopic treatment 14 (52 %)
Surgical treatment 6 (22 %)
BMI (kg/m2) 22.18 ± 4.06
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Circulating Concentrations of Inflammatory
Cytokines (TNF-a, IL-6, IL-1b)
Plasma levels of TNF-awere significantly higher in PC patients
(mean cytokine level: 22.15 pg/ml; range: 20.6–30.1 pg/ml)
and CP patients (23.1 pg/ml; range: 19.2–53.6 pg/ml) as
compared with the controls (13 pg/ml; range: 9.7–15.2 pg/ml)
(p\0.0002); however, there was no difference in TNF-a
levels between CP and PC patients. In PC and CP patients, IL-6
serum levels were significantly higher (6.6 ± 4.89 and
7.3 ± 4.05 pg/ml, respectively,) than in the control group
(3.3 ± 1.44 pg/ml) (p\0.0001).There was no statistically
significant difference between PC and CP IL-6 levels. Serum
IL-1b level in patients with pancreatic carcinoma and CP did
not differ from those in normal individuals (Fig. 2).
Fasting plasma TNF-a was found to be higher in the
severe stage of CP (Cambridge 3) (33.2 pg/ml) compared
to the moderate CP (Cambridge 2) (20.65 pg/ml),
(p\ 0.047). There was no other statistically significant
association between cytokines serum level and clinicopa-
tolological data of analyzed PC and CP groups.
There was no other statistically significant association
between cytokines serum level and alcohol and smoking of
analyzed PC and CP groups.
Circulating Concentrations of Endothelial
Dysfunction Biomarkers
As shown in Fig. 3, there was a significantly higher con-
centration of thrombomodulin in the sera of patients with
PC (p\ 0.05), compared with healthy controls. Moreover,
there were no differences between both pancreatic groups
and the controls healthy volunteers in E-selectin and
endothelin-1 levels (Fig. 3). Concentration of E-selectin in
the sera of patients with chronic alcoholic pancreatitis was
higher compared with the patients with idiopathic etiology,
(38.7 vs 17.4 ng/ml; p = 0.049), but the statistical differ-
ence was marginal.
Plasma levels of ICAM were significantly higher in PC
patients (mean cytokine level: 931 ng/ml; range: 508–1254
ng/ml) compared with CP patients (492 ng/ml; range
334–712 ng/ml) and control group (290 ng/ml; range
264–368 ng/ml; p = 0.0053) (Fig. 4). Additionally, pancre-
atic cancer patients who were smokers had significantly
higher concentrations of ICAM in the sera (1124 vs 496 ng/
ml; p = 0.03), compared with patients who never smoked.
Plasma levels of VCAM in PC patients (mean cytokine
level: 1511 ng/ml; range 1278–2090 ng/ml) were signifi-
cantly different from those with CP (1080 ng/ml; range
886–1530 ng/ml) and control group (840 ng/ml; range
596–976 ng/ml), though no differences in VCAM levels were
found between CP patients and healthy volunteers (Fig. 4).
Discussion
Several cytokines, chemokines, and their receptors have
been analyzed in cancer patients and animal models. These
molecules of inflammation have multiple functions ranging
from mediation of inflammation, immune function, angio-
genesis, and ultimately metastasis [11]. Additionally sub-
stantial evidence supports a role of chronic subclinical
inflammation and activation of the immune system in the
pathogenesis of insulin resistance and endothelial dys-
function in the development of type 2 diabetes [12, 13].
Chronic inflammatory states are associated with many
types of human malignancies, but its role in pancreatic
cancer is not fully understood. Previous correlative studies
in patients with pancreatic cancer have emphasized the
potential role of inflammatory chemokines in tumor resis-
tance to therapy [14].
Adiponectin is a protein that is produced largely by
white adipose tissue (20). It can greatly affect wide range
of disorders, including cardiovascular diseases, type 2
diabetes, metabolic syndrome, and rheumatoid arthritis
[15]. Adiponectin has been found to have a protective role
in several types of malignancies in vivo, particularly those
related to the obesity [16–18]. In the present study, plasma
level of adiponectin in PC patients was significantly higher
than in the control group. This finding is in accordance
with a previous case–control study that showed that adi-
ponectin was significantly elevated in 72 patients with PC
as compared to control subjects [19]. Similarly in Dalam-
aga et al. [20] study demonstrated high adiponectin levels,
which were independently associated with PC. Moreover,
they documented the presence of both adiponectin recep-
tors (AdipoR1 and AdipoR2) in PC tumor tissue. In con-
trast, another study reported that low prediagnostic levels
of circulating adiponectin were associated with elevated
risk of pancreatic cancer [21]. Recently, results from a
case–control study nested within European Prospective
Fig. 1 Analysis of adiponectin serum levels in patients with pancre-
atic cancer (PC), chronic pancreatitis (CP), and the control group
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Investigation into Cancer and Nutrition were published
[22]. They observed a nonsignificant decrease in PC risk
with increasing adiponectin level, but after evaluation of
additional factors, they concluded that decreased PC risk
may be restricted to never smoking women, whereas
smokers tended to have an increase in risk. One explana-
tion for the different findings regarding adiponectin levels
are changes in the metabolic profile over time. In healthy
subjects decreased adiponectin levels can predict an
increase in PC risk, but during PC development and in
advanced cancer stage, adiponectin levels can elevate
rapidly. Generally, low adiponectin is associated with
obesity and they predict PC. During advanced stages of the
disease, adiponectin elevate rapidly either to compensate
for insulin resistance and/or in response to loss of weight.
Additionally, increased adiponectin level in PC patients
could also be compensatory response to the inflammation,
which is characteristic for this type of cancer [23]. Adi-
ponectin is generally considered as an anti-inflammatory
agent although there have been studies also reporting
proinflammatory properties [24, 25].
In the current study, the levels of adiponectin were similar
in patients with pancreatic adenocarcinoma and CP and were
higher than in the control group. These results are consistent
with previous findings showing that adiponectin concentra-
tions were similar among patients with benign and malignant
disease (autoimmune pancreatitis, CP, pancreatic cancer, and
intraductal papillary mutinous tumors of the pancreas) [26].
However, our finding regarding elevated serum adiponectin
level in pancreatic cancer and CP cases is in disagreement
with a study of Chang et al. [19]. They found that the median
level of adiponectin for PC was significantly higher than
those for CP and suggested that adiponectin could be useful
in the differential diagnosis of PC and CP.
Fig. 2 Analysis of TNF-a, IL-
6, and IL-1b levels in sera
obtained from patients with
pancreatic cancer (PC), chronic
pancreatitis (CP), and the
control group
Fig. 3 Analysis of
thrombomodulin, E-selectin,
and endothelin-1 levels in sera
obtained from patients with
pancreatic cancer (PC), chronic
pancreatitis (CP), and the
control group
Fig. 4 Analysis of ICAM and VCAM levels in sera obtained from
patients with pancreatic cancer (PC), chronic pancreatitis (CP), and
the control group
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In our study, patients with pancreatic adenocarcinoma
and chronic alcoholic pancreatitis had elevated circulating
levels of IL-6 and TNF-a, but not IL-1b compared with the
levels in healthy individuals. Our results are in agreement
with other studies, which reported elevated TNF-a serum
levels in patients with different types of cancers compared
with normal subjects [14, 27, 28]. Recently, Błogowski
et al. also found that patients with pancreatic adenocarci-
noma had significantly higher systemic TNF-a level than
did individuals diagnosed with other pancreatic malignan-
cies [29]. In contrast, Ebrahimi et al. [5] reported no dif-
ference in TNF-a serum levels between PA patients and
healthy controls.
In our study, we observed significantly elevated IL-6
serum levels in patients with pancreatic adenocarcinoma,
similar to previous studies [5, 14, 30, 31]. Additionally,
plasma levels of IL-6 in patients with CP were significantly
higher than those in control group, with no differences
between CP patients and PC patients. IL-6 exerts pleio-
tropic functions on various cells that control inflammatory
diseases as well as models of inflammation-associated
cancer [32]. In pancreatic cancer, IL-6 increases macro-
phage recruitment and pancreatic tumor initiation. The
tumor-associated macrophages exert their effect in part by
increasing fibrosis in pancreatic adenocarcinoma PC [7].
In our study, we could not establish significant relation
between TNF-a and IL-6 serum levels and several clinical
factors of studied patients, probably due to relatively lim-
ited number of patients. For example Dima et al. showed
that elevated serum levels of TNF-a correlated with tumor
grade and overall survival in patients with PC. In their
studies, however, no significant association was observed
between tumor size, nodal status, and level of TNF-a [14].
Karayiannakis et al. [33] found elevated serum level of
TNF-a in patients with metastatic PC compared with non-
metastatic disease. It is worth noting that we excluded from
this study all patients with obvious confounding clinical
conditions known to raise IL-6 level such as acute
inflammatory activity in the pancreas or abnormal liver
function. Some authors have suggested that high IL-6
serum levels may also relate to high bilirubin levels [34]. In
some studies, increased TNF-a levels are associated with
weight loss in patients with pancreatic adenocarcinoma and
gastrointestinal cancer but in our study serum TNF-a levels
did not differ between cachectic and non-cachectic PC
patients [33, 35].
Some data indicate that proinflammatory interleukins
may participate in the development of insulin resistance in
men by either suppressing insulin receptors tyrosine kinase
activity or reducing transmembrane glucose transporters
expression [32, 36]. In animal model, local IL-6 production
in the pancreas was induced by endothelial cells and
proinflammatory cells infiltrating the pancreatic islets [37].
In autoimmune forms of diabetes, conflicting data on IL-6
serum levels have been reported. Some groups reported
lower levels of serum IL-6 in children with type 1 diabetes,
while others have found normal or even increased levels of
IL-6 [38]. Circulating IL-6 levels have been reported to be
elevated in subjects with impaired glucose tolerance or
type 2 diabetes [32, 39]. Therefore, we hypothesize that
increased plasma IL-6 and TNF-a in pancreatic diseases
may trigger disturbances in glucose homeostasis. In our
previous study, we showed plasma IL-6 to be elevated in
patients with CP compared to the healthy controls; how-
ever, we did not characterize CP patients for glucose tol-
erance [30]. In present study, a correlation has not been
found between TNF-a, IL-6, IL-1b, and endocrine dys-
function in CP and PC patients. The endocrine dysfunction
requires multiple cytokines interacting with or augmenting
each other effect in both groups of patients. Hansen et al.
[40] evaluated IL-6 in 16 patients with CP with and without
diabetes during an oral glucose tolerance test. They showed
that patient with CP and secondary DM in contrast to
patients with CP and NGT exhibit elevated plasma levels
of IL-6, suggesting that increased plasma levels of IL-6 are
consequences of the diabetic state, rather than playing
primary roles in the development of diabetes. Another
study suggested that serum levels of IL-6 are dependent on
the stage of the disease. In particular, high IL-6 levels were
noted in early phases of type 1 diabetes indicating that this
cytokine may play a role in destruction of islet cells. With
regard to type 2 diabetes, IL-6 levels in serum were found
to be elevated in many patients with this disease and could
be used as predictors for atherosclerosis development [32].
Okada et al. [31] have also suggested a high diagnostic
accuracy of IL-6 serum concentration assessment in dif-
ferential diagnosis between CP and pancreatic adenocar-
cinoma. They reported that IL-6 serum levels were
detectable only in 54.5 % patient with PA, 8 % with CP,
and 4 % of healthy volunteers. In our study, there was no
difference between IL-6 serum levels in PA and CP
patients. According to the results observed by other authors
IL-6 serum level may be elevated in CP patients [30]. In
contrast, the study of Shah et al., which analyzed cytokine
profile in CP patients receiving antioxidant therapy
(ANTICIPATE trial), showed low values of IL-6 levels
[41]. The results of published studies suggested that cyto-
kine levels measured in blood may not necessarily reflect
their activity at the pancreatic parenchymal level [41].
We measured also another important mediator of
inflammation, IL-1b in patients with CP and pancreatic
cancer. Interleukin 1beta is known as a promoter of tumor
angiogenesis, invasiveness, and metastasis [14]. We found
that IL-1b was not significantly increased in the sera of
patients with PC compared with those of patients with CP
or healthy individuals.
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Several proinflammatory cytokines, acute phase-reac-
tants, and cell adhesion molecules play a pivotal role in
chronic subclinical inflammation due to atherosclerosis and
type 2 diabetes, but understanding of the interrelations of
these molecules is still needed in CP and pancreatic cancer
patients. In both groups of patients, acinar atrophy, ductal
metaplasia, and a strong stroma reaction by fibroblastic
proliferation can be observed. Endothelial dysfunction can
be detected by measurement of elevated plasma levels of
cellular adhesion molecules (CAMs), including E-selectin,
intercellular adhesion molecule 1 (ICAM-1), and vascular
cell adhesion molecule 1 (VCAM-1). Cell adhesion mole-
cules, like ICAM-1 or VCAM-1, are known to play an
important role in cell–cell interactions, such as leukocyte–
endothelium adhesion and subsequent migration of inflam-
matory cells into the tissue or adhesion-dependent immune
responses [42]. Up-regulation of cell adhesion molecules in
inflammation or malignancy promotes adhesion of leuko-
cytes to the endothelium and thereby provides the first step
for extravascular passage of inflammatory cells. Enhanced
VCAM and ICAM expression has been found in human
colon, breast, and lung carcinoma cells [43]. On the other
hand, some authors also suggested that in solid pseudopap-
illary tumor, which is a rare neoplasm of pancreas, loss of
adhesion complex due to gene mutation results in instability
of the complex and dissociation of the tumor cells to form
the pseudopapillary pattern [44]. The role of ICAM-1 and
VCAM-1 in the adhesion of neutrophils and lymphocytes to
endothelium and cells of epithelial origin suggests that they
may be important in the immunologic response in CP and
pancreatic cancer. In our study, ICAM-1 values in sera of
pancreatic cancer and CP patients were significantly ele-
vated compared with the sera patients from control group.
These results are consistent with previous findings showing
that overexpression of adhesion molecules is characteristic
for CP and PC patients [45]. Additionally, we have also
demonstrated significantly higher level of VCAM in PC
patients compared with CP and controls. Probably increased
serum level of IL-6 induces acute phase responses in the
liver, modulates macrophage differentiation, induces
epithelial cell proliferation and tumor growth, and activates
adhesion molecules on endothelial cells [32]. Few clinical
studies analyzed different types of adhesion molecule levels
in pancreatic diseases. Techezy et al. showed that activated
leukocyte cell adhesion molecule (ALCAM) values were
significantly elevated in PC patients compared with values
of patients with CP and healthy blood donors [46]. Saka-
moto et al. analyzed plasma concentrations of angiogenesis-
related factors such as platelet endothelial cell adhesion
molecule-1, (PECAM-1), in pancreatic and colon cancer and
also in hepatobiliary diseases. The concentrations of
PECAM-1 were not elevated in patients with PC but were
elevated in patients with colon cancer [47].
In our study, the correlation between ICAM-1 and VCAM-
1 serum levels in patients with PC with the clinical and
pathological parameters revealed mostly no significant find-
ings, which confirms the results of recently published studies.
Techezy et al. [46] evaluated the impact of elevated ALCAM
levels on patients with PC, and no significant differences were
found regarding sex, age, tumor stage, and tumor cell grading,
but they do not analyze endocrine insufficiency. Similarly,
Sakamoto et al. [47] evaluated the correlation between the
plasma concentrations of PECAM-1 and clinical features
including age, sex, tumor location, tumor size, TNM stage,
lymph node metastasis, and distant metastasis in all the
patients with PC. PECAM was significantly elevated only in
the older age group of patients—above 60 years. The results
of other studies suggested a potential role of adhesion mole-
cules in cancer cell metastasis through its impact on cell
migration, intracellular signaling and cell—matrix interaction
[48, 49]. In recently published studies, identified adhesion
molecules play important function in the induction of
chemoresistance in vitro [50]. Additionally, overexpression of
adhesion molecules has been previously shown to be a bad
prognostic factor for pancreatic adenocarcinoma [48, 51]. Our
study has showed elevation of ICAM in patients with jaundice
and with lymph node involvement. Although we could not
demonstrate the relation between distant metastases and
ICAM/VCAM, the expression of these molecules has been
previously shown to contribute to metastasis formation and
aggressive growth behavior of PC [49].
An additional adhesion molecule, which we analyzed
was E-selectin-1 (endothelial leukocyte adhesion mole-
cule-1), is expressed by endothelial cells, which are acti-
vated by cytokines released during the inflammatory
process and play an important role in neutrophil extrava-
sation into injured tissues. This adhesion molecule interacts
with carbohydrate ligands of cell surface and can bind to
cell-surface carbohydrate glycoproteins located on several
tumors also on pancreatic carcinoma cell lines. Further-
more, E-selectin is thought to play an important role in
immunologic reactions. In our study, serum level of E-se-
lectin and endothelin in patients with CP and PC was not
different from the control group. Our results are in agree-
ment with results reported by Tempia-Caleira et al. [52].
They demonstrated that many pancreatic adenocarcinomas
do not show elevated expression of E-selectin.
In this study, we also found increased level of thrombo-
modulin in patients with PC compared with CP and controls
patients. Results of published studies showed that expression
of inhibitors of coagulation, including tissue factor pathway
inhibitor, antithrombin III, heparin cofactor II, protein C, free
protein S, and thrombomodulin, is decreased in patients with
pancreatic carcinoma [53, 54]. Other authors similarly to our
results report that circulating levels of thrombomodulin were
elevated in patients with pancreatic carcinoma [55]. Future
Dig Dis Sci (2016) 61:1121–1129 1127
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work is needed to establish the exact role of thrombomodulin
in patients with PC.
In summary, our data indicate that patients with pan-
creatic carcinoma and CP express high levels of several
cytokines compared with healthy individuals, especially
adiponectin, TNF-a, and IL-6. Serum TNF-a and ICAM
concentrations coordinately increase in advanced CP.
Furthermore, especially in PC subjects, elevated markers of
endothelial dysfunction are present. This study provides
additional evidence that changes in inflammatory cytokine
and adhesion molecules in PC and CP are not likely related
to endocrine disorders.
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